Compare Monster Beverage Corp (MNST) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Nuwellis Inc — how do they compare? Monster Beverage Corp trades at $43.62 (market cap $85.51B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: Monster Beverage Corp is far larger — about 38868.2× Nuwellis Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Nuwellis Inc for 26 Days on average.
| MNST | NUWE | |
|---|---|---|
Market Cap | $85.51B | $2.20M |
Volume | 8,569,709 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $146.65 |
52-Week Low | $33.16 | $0.68 |
Typical Hold Time | 72 Days | 26 Days |
Enterprise Value | $83.81B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $42.88, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS of $0.30 beat estimates, revenue grew to $8.29 billion in 2025, and net income margin stands at 23.08%. A 1:2 stock split is scheduled for August 11, 2026. Analyst consensus is a 'Buy' with a $98.22 price target, but technical indicators show selling pressure near current levels.
The outlook for MNST is mixed: robust earnings growth and zero long-term debt support upside, but high valuation ratios (P/E of 40.42) and bearish technicals pose near-term risks. International expansion, particularly a 35% sales surge overseas, offers growth potential, though regulatory challenges in markets like India and inflation pressures could hinder performance. The stock's rich pricing requires sustained execution to justify further gains.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
